Buy HCWB by Nov 28, 2026.

Did $HCWB just include an IL-15 into their drug pipeline? Yes, HCW Biologics (NASDAQ: $HCWB) announced that they have officially incorporated a TGF-β trap and IL-15 fusion moiety into their second-generation drug pipeline. The company revealed that human clinical data showed this specific IL-15 fusion successfully promoted the expansion of Natural Killer (NK) cells and progenitor CD8+ T cells while remaining well-tolerated in cancer patients. This directly aligns with the broader investment framework talked about ImmunityBio ($IBRX). It highlights a …